# Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

> **NCT03463252** · PHASE2,PHASE3 · RECRUITING · sponsor: **West China Second University Hospital** · enrollment: 224 (estimated)

## Conditions studied

- Endometrial Cancer
- Atypical Endometrial Hyperplasia

## Interventions

- **DRUG:** Progesterone
- **DEVICE:** Mirena®
- **DRUG:** GnRH agonist

## Key facts

- **NCT ID:** NCT03463252
- **Lead sponsor:** West China Second University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2021-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03463252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03463252, "Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03463252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*